ITCI Intra-Cellular Therapies Inc.

Intra-Cellular Therapies to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Intra-Cellular Therapies to Present at the 43rd Annual J.P. Morgan Healthcare Conference

BEDMINSTER, N.J., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 11:15 a.m. PT in San Francisco, CA.

The live and archived webcast can be accessed under "Events & Presentations" in the Investors section of the Company's website at .  Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.

About Intra-Cellular Therapies

Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. For more information, please visit .

Contact:

Intra-Cellular Therapies, Inc.

Juan Sanchez, M.D.

Vice President, Corporate Communications and Investor Relations

646-440-9333

Burns McClellan, Inc.

Cameron Radinovic

 

646-930-4406



EN
06/01/2025

Underlying

ITCIIntra-Cellular Therapies Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Intra-Cellular Therapies Inc.

 PRESS RELEASE
Free
ITCI Intra-Cellular ...

Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition...

Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc. Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and monotherapy; also approved for the treatment of schizophrenia in adults sNDA submitted to U.S. FDA for CAPLYTA® as adjunctive treatment for major depressive disorder; if approved, CAPLYTA® has potential to become a standard of care for most common depressive disorders CAPLYTA® adds to Johnson & Johnson’s robust lineup of therapies with $...

January 13, 2025 1 EN
 PRESS RELEASE
Free
ITCI Intra-Cellular ...

Intra-Cellular Therapies Settles CAPLYTA® (lumateperone) Patent Litiga...

Intra-Cellular Therapies Settles CAPLYTA® (lumateperone) Patent Litigation with Sandoz  BEDMINSTER, N.J., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it has entered into a settlement agreement with Sandoz Inc. (Sandoz) resolving patent litigation related to Intra-Cellular Therapies’ product CAPLYTA® (lumateperone). The litigation, which is pending in the U.S. District Court for the District of New...

January 10, 2025 1 EN
 PRESS RELEASE
Free
ITCI Intra-Cellular ...

Intra-Cellular Therapies to Present at the 43rd Annual J.P. Morgan Hea...

Intra-Cellular Therapies to Present at the 43rd Annual J.P. Morgan Healthcare Conference BEDMINSTER, N.J., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 11:15 a.m. PT in San Francisco, CA. The live and archived webcast can be accessed...

January 6, 2025 1 EN
 PRESS RELEASE
Free
ITCI Intra-Cellular ...

Intra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD...

Intra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College of Neuropsychopharmacology Annual Meeting Presentations complement topline data with new data from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy for the treatment of major depressive disorder Data shows robust remission and response efficacy rates in patients taking CAPLYTA Robust improvements in anxiety symptoms were also observed in patients taking CAPLYTA as measured by the Generalized Anxiety Disorder Questionnaire (GAD-7) Pooled...

December 11, 2024 1 EN
 PRESS RELEASE
Free
ITCI Intra-Cellular ...

Intra-Cellular Therapies Submits Supplemental New Drug Application (sN...

Intra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA® (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy The sNDA submission is based on positive results from Studies 501 and 502 demonstrating CAPLYTA’s robust antidepressant efficacy and favorable safety and tolerability profileCAPLYTA, if approved as an adjunctive therapy in MDD, would be indicated for the treatment of three different major psychiatry indications affecting over 30 million adult patients in the US BEDMINSTER, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE)...

December 3, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch